Rise Advisors LLC Has $27,000 Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

Rise Advisors LLC cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 28.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 243 shares of the company’s stock after selling 99 shares during the period. Rise Advisors LLC’s holdings in Neurocrine Biosciences were worth $27,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of NBIX. Captrust Financial Advisors raised its holdings in Neurocrine Biosciences by 18.7% in the fourth quarter. Captrust Financial Advisors now owns 11,644 shares of the company’s stock worth $1,589,000 after purchasing an additional 1,836 shares during the period. Cetera Investment Advisers raised its holdings in shares of Neurocrine Biosciences by 46.5% during the fourth quarter. Cetera Investment Advisers now owns 8,169 shares of the company’s stock worth $1,115,000 after acquiring an additional 2,593 shares during the period. Driehaus Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 45.4% during the fourth quarter. Driehaus Capital Management LLC now owns 102,921 shares of the company’s stock worth $14,049,000 after acquiring an additional 32,114 shares during the period. Deutsche Bank AG raised its holdings in shares of Neurocrine Biosciences by 5.5% during the fourth quarter. Deutsche Bank AG now owns 461,782 shares of the company’s stock worth $63,033,000 after acquiring an additional 23,951 shares during the period. Finally, Ethic Inc. raised its holdings in shares of Neurocrine Biosciences by 34.4% during the fourth quarter. Ethic Inc. now owns 4,192 shares of the company’s stock worth $572,000 after acquiring an additional 1,073 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Ingrid Delaet sold 457 shares of Neurocrine Biosciences stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the transaction, the insider owned 4,730 shares of the company’s stock, valued at $638,550. This trade represents a 8.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the transaction, the director directly owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 186,960 shares of company stock valued at $23,955,553 in the last quarter. Company insiders own 4.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NBIX. Guggenheim raised their price objective on shares of Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Morgan Stanley raised their price objective on shares of Neurocrine Biosciences from $158.00 to $163.00 and gave the stock an “overweight” rating in a report on Friday. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. UBS Group lifted their price target on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday, July 9th. Finally, Royal Bank Of Canada lifted their price target on shares of Neurocrine Biosciences from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Friday. Eighteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $160.00.

Neurocrine Biosciences Trading Up 2.6%

Shares of NBIX stock opened at $144.10 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $154.61. The firm’s fifty day moving average price is $132.62 and its two-hundred day moving average price is $120.31. The firm has a market capitalization of $14.29 billion, a P/E ratio of 42.63, a PEG ratio of 1.04 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The company had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. During the same quarter last year, the firm posted $1.63 EPS. The company’s quarterly revenue was up 16.5% on a year-over-year basis. As a group, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.